Meningitis Vaccine Manufacturing: Fermentation Harvest Procedures Affect Purification - Careful analysis of an unusual precipitate identifies defects. - BioPharm International

ADVERTISEMENT

Meningitis Vaccine Manufacturing: Fermentation Harvest Procedures Affect Purification
Careful analysis of an unusual precipitate identifies defects.


BioPharm International Supplements
Volume 24, Issue 4, pp. s21-s26

ABSTRACT

The meningitis vaccine NeisVac-C is a group C meningococcal polysaccharide conjugated to tetanus toxoid. The polysaccharide is recovered from the Neisseria meningitidis cell capsule and is purified by base treatment with subsequent diafiltration to remove hydrolyzed cell impurities. Purified polysaccharide is clear to slightly cloudy. A recent group of successive lots contained large amounts of precipitate that had not been observed in 10 previous years of commercial manufacturing. The precipitate was mostly composed of the sodium salt of palmitic acid (C16:0) with lesser amounts of palmitoleic (C16:1), oleic (C18:1), stearic (C18:0) and myristic (C14:0) sodium salts. The elevated fatty acid levels that formed the precipitate were linked to a damaged pump used during harvest. Replacement of the damaged pump corrected the issue and >15 lots have since been produced without precipitation.


Photo courtesy of the authors
NeisVac-C is a vaccine that prevents the invasive disease caused by Neisseria meningitidis serogroup C. The active ingredient is a polysaccharide–protein conjugate. Each dose contains 10 g of de-O-acetylated group C meningococcal polysaccharide (GCMP) conjugated to 10-20 g of tetanus toxoid protein and adsorbed onto 0.5 mg of aluminum as aluminum hydroxide in saline.


Figure 1: Visible precipitation during GCMP purification.
The GCMP is isolated from the culture medium of Neisseria meningitidis by microfiltration. The microfiltration permeate is concentrated and diafiltered to remove small soluble fermentation components. The major purification step is a saponification reaction in which the GCMP is refluxed with high concentrations of base for several hours. After diafiltration, the mixture typically appears clear to slightly cloudy. A recent cohort of successive GCMP lots contained a precipitate that had not previously occurred in ten years of commercial manufacturing (see Figure 1). This article describes the problem, the root cause analysis, and the corrective actions.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here